Medical Radiology and Radiation Safety. 2023. Vol. 68. № 1
DOI: 10.33266/1024-6177-2023-68-1-86-91
V.I. Chernov1,2, E.A. Dudnikova1, R.V. Zelchan1,2, O.D. Bragina1,2,
A.A. Medvedeva1, A.N. Rybina1, A.V. Muravleva1, T.L. Kravchuk1, V.E. Goldberg1
Single-Photon Emission Computed Tomography with 99mTс-1-Thio-D-glucose in Evaluation of the Effectiveness and Prediction of the Results of Treatment of Lymphoproliferative Diseases
1Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia
2 Research Centrum for Oncotheranostics, Tomsk Polytechnic University, Tomsk, Russia
Contact person: V.I. Chernov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Study of 99mTc-1-thio-D-glucose (99mTc-TG) SPECT using fore possibility to assess the effectiveness of therapy and predict the results of lymphomas treatment.
Material and methods: We analyzed 99mTc-TG SPECT data of 30 people with malignant lymphomas: before treatment (SPECT1), after two courses (SPECT2) and after completion of chemotherapy (SPECT3).
Results: By the results of SPECT2 analyzing, a complete metabolic response after two courses of chemotherapy (SPECT2–) was observed in 15 patients (50 %). In 15 patients, after 2 cycles of chemotherapy, a partial metabolic response (12 people) or no metabolic response
(3 people) was established. These patients constituted the SPECT2+ group.
After completion of chemotherapy, a complete metabolic response (SPECT3–) was diagnosed in 21 (70 %) patients. This effect was obtained in 15 (100 %) patients with SPECT2– and in 6 patients (40 %) with SPECT2+. Of the 15 patients in the SPECT2+ group, 9 (60 %) patients after completion of chemotherapy were diagnosed with a partial metabolic response (6 people) or metabolic progression (3 people).
By two-year follow-up of patients, show that remission was observed in 23 (77 %) patients (complete remission in 15 people, uncertain complete remission in 8 patients). The relapse group consisted of 7 (23 %) cases, while 4 patients had a relapse of the disease, and 3 had progression. In SPECT2+ group, relapse of the disease was observed in 6 (40 %) cases, and remission in 9 (60 %) patients. While in SPECT2– group 1 (7 %) person relapse was diagnosed and 14 (93 %) were in remission (p<0.05).
Conclusion: 99mTc-TG SPECT makes it possible to evaluate the results of lymphomas treatment with high efficiency. The presence of a complete metabolic response of the tumor after two courses of therapy indicates a high level of disease-free survival.
Keywords: 99mTc-1-thio-D-glucose, single photon emission computed tomography, Hodgkin’s lymphoma, Non-Hodgkin’s lymphomas, lymphoma therapy, prognosis
For citation: Chernov VI, Dudnikova EA, Zelchan RV, Bragina OD, Medvedeva AA, Rybina AN, Muravleva AV, Kravchuk TL, Goldberg VE. Single-Photon Emission Computed Tomography with 99mTс-1-Thio-D-glucose in Evaluation of the Effectiveness and Prediction of the Results of Treatment of Lymphoproliferative Diseases. Medical Radiology and Radiation Safety. 2023;68(1):86–91. (In Russian). DOI: 10.33266/1024-6177-2023-68-1-86-91
References
1. Poddubnaya I.V., Savchenko V.G. Rossiyskiye Klinicheskiye Rekomendatsii po Diagnostike i Lecheniyu Zlokachestvennykh Limfoproliferativnykh Zabolevaniy = Recommendations for the Diagnosis and Treatment of Malignant Lymphoproliferative Diseases. Мoscow Publ., 2018. 470 c. (In Russ.).
2. Barrington S.F., Mikhaeel N.G., Kostakoglu L., et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J. Clin. Oncol. 2014;32:3048–3058. DOI: 10.1200/JCO.2013.53.5229.
3. Dreyling M., Thieblemont C., Gallamini A. et al. ESMO Consensus Conferences: Guidelines on Malignant Lymphoma. Part 2: Marginal Zone Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma. Ann Oncol. 2013;24:857–877. DOI: 10.1093/annonc/mds643.
4. Radford J., Illidge T., Counsell N. et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. New England Journal of Medicine. 2015;372;17:1598–1607. DOI: 10.1056/NEJMoa1408648.
5. Chanchikova N.G., Chernov V.I., Dudnikova Ye.A., et al. The Role of 18F-FDG PET/CT in Evaluation of Therapy Effectiveness and Prognosis of Lymphomas. Byulleten Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2021;20;2:120–129. DOI: org/10.20538/1682-0363-2021-2-120-129 (In Russ.).
6. Chernov V.I., Dudnikova Ye.A., Goldberg V.Ye., et al. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2018;63;6:41–50. DOI: 10.12737/article_5c0b8d72a8bb98.40545646 (In Russ.).
7. Chanchikova N.G., Dudnikova Ye.A., Karlova Ye.A., et al. Possibilities of 18F-FDG PET/CT in the diagnosis and staging of lymphomas. Voprosy Onkologii = Problems in Oncology. 2019;65;1:147–153. DOI: org/10.37469/0507-3758-2019-65-1-147-153 (In Russ.).
8. Chernov V.I., Dudnikova Ye.A., Goldberg V.Ye., et al. Single-Photon Emission Computerized Tomography in the Diagnosis and Monitoring of Lymphomas. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2019;64;3:58–63. DOI: 10.12737/article_5cf3dfefe60b13.90120976 (In Russ.).
9. Zeltchan R., Medvedeva A., Sinilkin I., et al. Experimental Study of Radiopharmaceuticals Based on Technetium-99m Labeled Derivative of Glucose for Tumor Diagnosis. IOP Conference Series. Materials Science and Engineering. 2016. DOI: 10.1088/1757-899X/135/1/012054.
10. Zelchan R.V., Medvedeva A.A., Sinilkin I.G., et al. Study of Functional Suitability Tumor Tropism Radiopharmaceuticals 99mTc-1-Thio-D-Glucose in the Experiment. Molekulyarnaya Meditsina = Molecular Medicine. 2018;16;2:54–57. DOI: https://doi.org/10.29296/24999490-2018-03-11 (In Russ.).
11. Chernov V.I., Medvedeva A.A., Sinilkin I.G., et al. Development Radiopharmaceuticals for Nuclear Medicine in Oncology. Meditsinskaya Vizualizatsiya = Medical Visualization. 2016;2:63–66 (In Russ.).
12. Chernov V.I., Dudnikova Ye.A., Zelchan R.V., et al. The First Experience of Using 99mTc-1-Thio-d-Glucose for Single-Photon Emission Computed Tomography Imaging of Lymphomas. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2018;17;4:81–87. DOI: 10.21294/1814-4861-2018-17-4-81-87 (In Russ.).
13. Dudnikova Ye.A., Chernov V.I., Muravleva A.V., et al. Metabolic Single-Photon Emission Computed Tomography with the New Radiopharmaceutical 99mTc-1-Thio-D-Glucose in the Diagnosis and Monitoring of the Primary Breast Lymphoma (Case Report). Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2020;19;5:145–153. doi: 10.21294/1814-4861-2020-19-5-145-153 (In Russ.).
14. Muravleva A.V., Chernov V.I., Dudnikova Ye.A., et al. Metabolic single-Photon Emission Computed Tomography with «99mTc-1-Thio-D-Glucose» - New Possibilities for Hodgkin’s Lymphoma Staging. Rossiyskiy Elektronnyy Zhurnal Luchevoy Diagnostiki = Russian Electronic Journal of Radiology. 2021;11;3:171–177. DOI: 10.21569/2222-7415-2021-11-3-171-177 (In Russ.).
15. Chernov V., Dudnikova E., Zelchan R., et al. Phase I Clinical Trial Using [99mTc]Tc-1-Thio-D-Glucose for Diagnosis of Lymphoma Patients. Pharmaceutics. 2022;14:1274. https://doi.org/10.3390/pharmaceutics14061274.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.09.2022. Accepted for publication: 25.11.2022.